Similarly, non-alcoholic steatohepatitis associated with reduced gene and protein expression of CPS1 resulting in hyperammonemia49 might also be a target of OGA-inhibitors. The gene discussed is CPS1; the disease is metabolic dysfunction-associated steatohepatitis.